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Introduction {#bjs550270-sec-0005}
============

Radical resection for gastric cancer remains the mainstay for cure in patients with locally advanced disease. In the West it has been shown that long‐term survival can be improved further by adding perioperative chemotherapy[1](#bjs550270-bib-0001){ref-type="ref"}, [2](#bjs550270-bib-0002){ref-type="ref"}, [3](#bjs550270-bib-0003){ref-type="ref"}, whereas in studies from Japan, South Korea, China and Taiwan, adjuvant chemotherapy is usually recommended[4](#bjs550270-bib-0004){ref-type="ref"}, [5](#bjs550270-bib-0005){ref-type="ref"}. Classification of the extent of lymphadenectomy has changed over time, and is now classified as D0, D1 and D2 according to the Japanese Gastric Cancer Association (JGCA)[6](#bjs550270-bib-0006){ref-type="ref"}. Three European RCTs[7](#bjs550270-bib-0007){ref-type="ref"}, [8](#bjs550270-bib-0008){ref-type="ref"}, [9](#bjs550270-bib-0009){ref-type="ref"} have investigated D2 lymphadenectomy compared with a less extensive D1 lymphadenectomy. No study showed a survival advantage for D2 lymphadenectomy at 5 years, but the Dutch trial[10](#bjs550270-bib-0010){ref-type="ref"} was able to show a benefit at 15 years of follow‐up after exclusion of postoperative deaths. Despite these results, D1+/D2 lymphadenectomy has become widely used in the West. The present nationwide cohort study was undertaken to see whether there was a long‐term survival benefit for patients with gastric cancer undergoing D1+/D2 lymphadenectomy.

Methods {#bjs550270-sec-0006}
=======

This was a national quality register study including all patients in Sweden registered in the National Register of Oesophageal and Gastric cancer (NREV) from 2006 to 2017. The NREV, which has detailed clinical information on all patients with gastric cancer in Sweden, was cross‐matched with data from the Swedish National Patient Register, National Register of Education, Emigration Register and Death Register to obtain educational level, emigration status, time of death, and modified Charlson Co‐morbidity Index (CCI)[11](#bjs550270-bib-0011){ref-type="ref"}. The NREV has been validated previously and shown to be accurate for a variety of variables in more than 91 per cent of patients[12](#bjs550270-bib-0012){ref-type="ref"}. The Swedish National Patient Register has complete coverage of patient diagnostic codes in inpatient care from 1987, and for specialized outpatient care since 2001[13](#bjs550270-bib-0013){ref-type="ref"}. The form and structure of the data collection have been described previously[14](#bjs550270-bib-0014){ref-type="ref"}.

The study was approved by the Regional Ethics Committee (EPN Stockholm Dnr: 2016/1486‐32 and 2013/596‐31/3).

Study population {#bjs550270-sec-0007}
----------------

All patients undergoing resection for adenocarcinoma of the stomach and gastro‐oesophageal junction cancer type III were included. Patients who had a previous gastric resection or who had undergone proximal gastrectomy or pylorus‐preserving gastrectomy were excluded, as were those who had a resection described as palliative. Patients were classified by the extent of lymphadenectomy as having a D0, D1, D1+ or D2 procedure according to the fourth English version of the JGCA treatment guidelines for distal and total gastrectomy[6](#bjs550270-bib-0006){ref-type="ref"}. An *a priori* decision grouped D1+ and D2 lymphadenectomies together as lymphadenectomy station criteria are similar and correspond to more radical resection, whereas D0 and D1 lymphadenectomy were grouped and analysed together as they represent limited lymphadenectomies.

Statistical analysis {#bjs550270-sec-0008}
--------------------

Data are presented as mean(s.d.) values or as counts with percentages. Statistical analyses were performed with the χ^2^ test or Fisher\'s exact test for categorical variables, and Student\'s *t* test for continuous variables. Survival was calculated by use of the Kaplan--Meier method and analysed with the log rank test. Multivariable analysis of factors affecting survival was done by Cox proportional hazards modelling, and presented with hazard ratios (HRs) and 95 per cent confidence intervals. Variables in the model included: age (as a continuous variable), sex, CCI (categorized as 0--1, 2 and 3 or above), ASA grade (categorized as I, II, III, IV, V or missing), clinical tumour stage according to TNM8 (grouped as stage I, II, III, IV and missing), surgical procedure (distal or total gastrectomy), multivisceral resection (includes any additional organ resection in addition to gastrectomy, categorized as no or yes), preoperative chemotherapy (no, yes or missing), educational level (categorized as 9 years or less, 10--12 years, more than 12 years or missing), and calendar year of surgery (grouped as 2006--2009, 2010--2013 and 2014--2017). The variables were chosen based on clinical importance and statistical significance in the model. Educational level was included as it has been shown to be a possible confounder for survival[15](#bjs550270-bib-0015){ref-type="ref"}. The significance level was set at *P* = 0·100 or less for a variable to be included in the model.

All statistical analyses were performed with IBM SPSS® Statistics version 25 (IBM, Armonk, New York, USA).

Results {#bjs550270-sec-0009}
=======

A total of 6761 patients were diagnosed with gastric and gastro‐oesophageal junction type III cancer. Among these, 1677 had non‐palliative distal or total gastrectomy for adenocarcinoma (*Fig*. [1](#bjs550270-fig-0001){ref-type="fig"}). The extent of lymphadenectomy was D0/D1 in 1206 patients (71·9 per cent) and D1+/D2 in 471 (28·1 per cent). The complete distribution was 930 D0 (55·5 per cent), 276 D1 (16·5 per cent), 126 D1+ (7·5 per cent) and 345 D2 (20·6 per cent).

![Flow chart of patient selection](BJS5-4-424-g001){#bjs550270-fig-0001}

Baseline characteristics of patients are presented in *Table*  [1](#bjs550270-tbl-0001){ref-type="table"}. In general, patients who had a D1+/D2 procedure were younger with a higher level of education, a slightly lower ASA grade and a more advanced tumour stage (stage III or above: 24·8 per cent compared with 14·6 per cent in the D0/D1 group). D1+/D2 lymphadenectomy became more popular during the latter part of the study period, comprising 20·8 per cent of resections in 2006--2009 *versus* 41·2 per cent in 2014--2017.

###### 

Baseline characteristics of patients undergoing limited D0/D1 lymphadenectomy or more extensive D1+/D2 dissection

                                                                 D0/D1 (*n* = 1206)   D1+/D2 (*n* = 471)   Overall (*n* = 1677)     *P* [†](#bjs550270-note-0003){ref-type="fn"}
  ------------------------------------------------------------- -------------------- -------------------- ---------------------- --------------------------------------------------
  **Age (years)** [\*](#bjs550270-note-0002){ref-type="fn"}            70(11)               65(12)                69(12)          \< 0·001[§](#bjs550270-note-0005){ref-type="fn"}
  **Sex**                                                                                                                                               0·602
  M                                                                  698 (57·9)           266 (56·5)            964 (57·5)       
  F                                                                  508 (42·1)           205 (43·5)            713 (42·5)       
  **BMI (kg/m^2^)** [\*](#bjs550270-note-0002){ref-type="fn"}        25·1(4·45)           25·2(4·43)            25·2(4·44)          0·682[§](#bjs550270-note-0005){ref-type="fn"}
  **ASA grade**                                                                                                                   \< 0·001[‡](#bjs550270-note-0004){ref-type="fn"}
  I                                                                  310 (25·7)           168 (35·7)            478 (28·5)       
  II                                                                 591 (49·0)           223 (47·3)            814 (48·5)       
  III                                                                252 (20·9)           66 (14·0)             318 (19·0)       
  IV                                                                  24 (2·0)             3 (0·6)               27 (1·6)        
  V                                                                    0 (0)                0 (0)                 0 (0)          
  Missing                                                             29 (2·4)             11 (2·3)              40 (2·4)        
  **Clinical tumour stage**                                                                                                                           \< 0·001
  I                                                                  402 (33·3)           120 (25·5)            522 (31·1)       
  II                                                                 312 (25·9)           167 (35·5)            479 (28·6)       
  III                                                                149 (12·4)           100 (21·2)            249 (14·8)       
  IV                                                                  27 (2·2)             17 (3·6)              44 (2·6)        
  Missing                                                            316 (26·2)           67 (14·2)             383 (22·8)       
  **Charlson Co‐morbidity Index**                                                                                                                       0·655
  0--1                                                               400 (33·2)           147 (31·2)            547 (32·6)       
  2                                                                  195 (16·2)           83 (17·6)             278 (16·6)       
  ≥ 3                                                                611 (50·7)           241 (51·2)            852 (50·8)       
  **Years of education**                                                                                                                              \< 0·001
  ≤ 9                                                                474 (39·3)           149 (31·6)            623 (37·1)       
  10--12                                                             455 (37·7)           193 (41·0)            648 (38·6)       
  \> 12                                                              186 (15·4)           111 (23·6)            297 (17·7)       
  Missing                                                             91 (7·5)             18 (3·8)             109 (6·5)        
  **Tumour location**                                                                                                                                 \< 0·001
  GOJ Siewert III                                                     37 (3·1)            52 (11·0)              89 (5·3)        
  Upper                                                               39 (3·2)             34 (7·2)              73 (4·4)        
  Middle                                                             386 (32·0)           205 (43·5)            591 (35·2)       
  Lower                                                              625 (51·8)           123 (26·1)            748 (44·6)       
  Whole                                                               25 (2·1)             23 (4·9)              48 (2·9)        
  Missing                                                             94 (7·8)             34 (7·2)             128 (7·6)        
  **Calendar year of surgery**                                                                                                                        \< 0·001
  2006--2009                                                         468 (38·8)           98 (20·8)             566 (33·8)       
  2010--2013                                                         469 (38·9)           179 (38·0)            648 (38·6)       
  2014--2017                                                         269 (22·3)           194 (41·2)            463 (27·6)       

Values in parentheses are percentages unless indicated otherwise;

values are mean(s.d.). GOJ, gastro‐oesophageal junction.

χ^2^ test, except

Fisher\'s exact test and

Student\'s *t* test.

Surgical details are presented in *Table*  [2](#bjs550270-tbl-0002){ref-type="table"}. The distribution between total and distal gastrectomy was almost equal in the overall cohort. There was, however, a difference in the extent of lymphadenectomy related to the type of gastrectomy, with more D1+/D2 being performed in patients having a total gastrectomy (74·5 per cent) than in those having a distal gastrectomy (25·5 per cent). Preoperative chemotherapy was more commonly used in patients who subsequently underwent more extensive lymphadenectomy. Multivisceral resection included pancreatosplenectomy or splenectomy alone, as well as colectomy, adrenalectomy, cholecystectomy, and resection of the diaphragm, small bowel and liver. Multivisceral resection was associated more frequently with D1+/D2 lymphadenectomy. There was no significant difference regarding the use of laparoscopy or open surgery between the groups.

###### 

Surgical details of patients undergoing limited D0/D1 lymphadenectomy or more extensive D1+/D2 dissection

                                   D0/D1 (*n* = 1206)   D1+/D2 (*n* = 471)   Overall (*n* = 1677)   *P* [\*](#bjs550270-note-0007){ref-type="fn"}
  ------------------------------- -------------------- -------------------- ---------------------- -----------------------------------------------
  **Surgical procedure**                                                                                              \< 0·001
  Distal gastrectomy                   770 (63·8)           120 (25·5)            890 (53·1)       
  Total gastrectomy                    436 (36·2)           351 (74·5)            787 (46·9)       
  **Laparoscopic surgery**                                                                                               0·111
  No                                  1171 (97·1)           450 (95·5)           1621 (96·7)       
  Yes                                   35 (2·9)             21 (4·5)              56 (3·3)        
  **Preoperative chemotherapy**                                                                                       \< 0·001
  No                                   870 (72·1)           191 (40·6)           1061 (63·3)       
  Yes                                  322 (26·7)           280 (59·4)            602 (35·9)       
  Missing                               14 (1·2)              0 (0)                14 (0·8)        
  **Multivisceral resection**          *n* = 1197           *n* = 469             *n* = 1666                          \< 0·001
  No                                  1004 (83·9)           312 (66·5)           1316 (79·0)       
  Yes                                  193 (16·1)           157 (33·5)            350 (21·0)       
  **Pancreatosplenectomy**             *n* = 1197           *n* = 469             *n* = 1666                          \< 0·001
  No                                  1178 (98·4)           446 (95·1)           1624 (97·5)       
  Yes                                   19 (1·6)             23 (4·9)              42 (2·5)        
  **Splenectomy**                      *n* = 1197           *n* = 469             *n* = 1666                          \< 0·001
  No                                  1118 (93·4)           369 (78·7)           1487 (89·3)       
  Yes                                   79 (6·6)            100 (21·3)            179 (10·7)       
  **Emergency operation**              *n* = 1198                                 *n* = 1669                             0·457
  No                                  1162 (97·0)           460 (97·7)           1622 (97·2)       
  Yes                                   36 (3·0)             11 (2·3)              47 (2·8)        

Values in parentheses are percentages.

χ^2^ test.

D1+/D2 lymphadenectomy resulted in a significantly greater lymph node yield and, although 30‐ and 90‐day postoperative mortality was similar, there was a slightly higher overall 30‐day complication rate in the D1+/D2 group (*Table*  [3](#bjs550270-tbl-0003){ref-type="table"}).

###### 

Lymph node yield and postoperative complications in patients undergoing limited D0/D1 lymphadenectomy or more extensive D1+/D2 dissection

                                                                      D0/D1 (*n* = 1206)   D1+/D2 (*n* = 471)   Overall (*n* = 1677)     *P* [†](#bjs550270-note-0010){ref-type="fn"}
  ------------------------------------------------------------------ -------------------- -------------------- ---------------------- --------------------------------------------------
  **No. of lymph nodes** [\*](#bjs550270-note-0009){ref-type="fn"}                                                                    
  Distal gastrectomy                                                  16(12) (*n* = 693)   25(15) (*n* = 106)    17(13) (*n* = 799)    \< 0·001[‡](#bjs550270-note-0100){ref-type="fn"}
  Total gastrectomy                                                   19(13) (*n* = 398)   31(18) (*n* = 301)    24(16) (*n* = 699)    \< 0·001[‡](#bjs550270-note-0100){ref-type="fn"}
  **30‐day postoperative mortality**                                                                                                  
  No                                                                     1179 (97·8)           460 (97·7)           1639 (97·7)                             0·905
  Yes                                                                      27 (2·2)             11 (2·3)              38 (2·3)        
  **90‐day postoperative mortality**                                                                                                  
  No                                                                     1143 (94·8)           451 (95·8)           1594 (95·1)                             0·407
  Yes                                                                      63 (5·2)             20 (4·2)              83 (4·9)        
  **Overall complications**                                               *n* = 1105           *n* = 410             *n* = 1515       
  No                                                                      811 (73·4)           264 (64·4)           1075 (71·0)                             0·001
  Yes                                                                     294 (26·6)           146 (35·6)            440 (29·0)       

Values in parentheses are percentages unless indicated otherwise;

values are mean(s.d).

χ^2^ test, except

Student\'s *t* test.

Overall long‐term survival was slightly better after D1+/D2 lymphadenectomy, with a median overall survival of 41·5 months and 5‐year survival rate of 43·7 per cent compared with 38·5 months median overall survival and 5‐year survival rate of 38·5 per cent for D0/D1, although the difference was not statistically significant (*P* = 0·116) (*Fig*. [2](#bjs550270-fig-0002){ref-type="fig"}). After adjustment for confounders, multivariable analysis indicated that survival was significantly longer after D1+/D2 lymphadenectomy compared with the D0/D1 procedure (HR 0·81, 95 per cent c.i. 0·68 to 0·95; *P* = 0·012) (*Table*  [4](#bjs550270-tbl-0004){ref-type="table"}).

![Kaplan--Meier analysis of overall survival in patients undergoing limited or more extensive lymphadenectomy D0/D1, limited lymphadenectomy; D1+/D2, more extensive dissection. *P* = 0·116 (log rank test).](BJS5-4-424-g002){#bjs550270-fig-0002}

###### 

Cox proportional hazards analysis of the impact of lymphadenectomy on survival

                        D1+/D2 *versus* D0/D1                              
  -------------------- ----------------------- ------- ------------------- -------
  All patients            0·89 (0·77, 1·03)     0·107   0·81 (0·68, 0·95)   0·012
  Distal gastrectomy      0·61 (0·44, 0·84)     0·003   0·75 (0·54, 1·06)   0·100
  Total gastrectomy       0·86 (0·72, 1·03)     0·108   0·85 (0·70, 1·04)   0·111

Values in parentheses are 95 per cent confidence intervals. Adjusted for age, sex, Charlson Co‐morbidity Index, ASA grade, clinical tumour stage, surgical procedure (in analysis of all cases), multivisceral resection, preoperative chemotherapy, educational level, and calendar year of surgery. HR, hazard ratio.

When stratified by surgical procedure, significantly better survival was found in patients having a distal gastrectomy and D1+/D2 lymphadenectomy compared with D0/D1 (5‐year survival rate of 59·6 *versus* 41·8 per cent respectively; *P* = 0·002). After total gastrectomy median overall survival was 33·6 months with a 5‐year survival rate of 38·7 per cent in the D1+/D2 group, compared with 30·8 months and 32·6 per cent respectively after D0/D1 lymphadenectomy (*P* = 0·125) (*Fig*. [3](#bjs550270-fig-0003){ref-type="fig"}).

![Kaplan--Meier analysis of overall survival after lymphadenectomy, stratified for surgical procedure D0/D1, limited lymphadenectomy; D1+/D2, more extensive dissection. Distal gastrectomy (DG): *P* = 0·002; total gastrectomy (TG): *P* = 0·125 (log rank test).](BJS5-4-424-g003){#bjs550270-fig-0003}

Discussion {#bjs550270-sec-0010}
==========

This study, based on a prospectively developed database from routine gastric cancer surgery in a Western population, has shown that extended lymphadenectomy (D1+/D2) performed during curatively intended gastrectomy offered better long‐term survival than limited lymphadenectomy (D0/D1). Although none of the three European randomized trials[7](#bjs550270-bib-0007){ref-type="ref"}, [8](#bjs550270-bib-0008){ref-type="ref"}, [9](#bjs550270-bib-0009){ref-type="ref"} detected a long‐term survival advantage following gastrectomy and D2 lymphadenectomy, compared with D1 lymphadenectomy, in two early trials[16](#bjs550270-bib-0016){ref-type="ref"}, [17](#bjs550270-bib-0017){ref-type="ref"} D2 lymphadenectomy was associated with high postoperative morbidity and mortality, mainly due to the routine inclusion of splenectomy and pancreatic tail resection. In the latest randomized trial conducted in Italy[18](#bjs550270-bib-0018){ref-type="ref"}, where splenectomy and pancreatic tail resection were not standard in D2 lymphadenectomy, postoperative morbidity and mortality were substantially lower. In the Dutch trial[10](#bjs550270-bib-0010){ref-type="ref"}, after 15 years of follow‐up and with exclusion of postoperative deaths, a survival benefit was detected. The notion that D2 dissection can nowadays be safely carried out in Western centres was supported by a previous national registry study[14](#bjs550270-bib-0014){ref-type="ref"} showing acceptable complication rates.

The traditional view is that the highest level of evidence is obtained from well designed and adequately powered RCTs. Such studies are not, however, always generalizable owing to specific patient entry criteria. On the other hand, well defined population‐based studies using data retrieved from well validated national registers, with minimal selection bias and accurate follow‐up information, reflect standard practice. The national NREV database includes detailed surgical data regarding the type of resection, including dissected lymph node stations. Most importantly, the validity and quality of the data in the NREV register have been recognized as high[12](#bjs550270-bib-0012){ref-type="ref"}. Some potential weaknesses must, however, be acknowledged. Detailed information on non‐surgical oncological treatments has been included only recently in the database, and was not available at the time of the present study. Although a significantly greater proportion of patients having the D1+/D2 procedure received chemotherapy, survival benefit estimates among this group remained after adjustment in the multivariable model. This suggests that chemotherapy might best be considered an adjunct to adequate lymphadenectomy as a means of improving survival after gastric cancer surgery.

Another potential problem is the risk of misclassification of the lymphadenectomy groups. There is a possibility of yielding no lymph nodes from a specific station, and of removal of nodes outside the registered extent of the resection. Information on specific lymphadenectomy stations was entered into the registry by the operating surgeon, but there has been no external validation of this. The study period covered modifications to the lymphadenectomy classifications from the second to the fourth English editions of the JGCA guidelines, with substantial change between the second and third editions[6](#bjs550270-bib-0006){ref-type="ref"}, [19](#bjs550270-bib-0019){ref-type="ref"}, [20](#bjs550270-bib-0020){ref-type="ref"}. Despite these changes, it was notable that a significantly higher lymph node harvest was found in the D1+/D2 group in the present study than in the D0/D1 group. It seems unlikely that misclassification of lymphadenectomy would have a large impact on the results of this study, as such a misclassification would most likely occur randomly, affecting each study group equally.

In Sweden, D1+/D2 lymphadenectomy was performed more commonly during total rather than distal gastrectomy, yet the greatest impact of the extent of lymphadenectomy on survival was seen in patients who had a distal gastrectomy. This difference accounts for a major part of the survival advantage in the adjusted Cox proportional hazards modelling, although it should be noted that lack of awareness of the latest JGCA guidelines on adequate lymphadenectomy during distal gastric cancer surgery may be important. Despite these limitations, this population‐based registry study of a nation\'s routine practice shows that long‐term survival after gastric cancer surgery is improved following gastrectomy with D1+/D2 compared with less extensive lymphadenectomy.
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